(GEHC) GE HealthCare Technologies - Ratings and Ratios

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a leading global provider of medical imaging, diagnostics, and patient monitoring solutions. The company, spun off from General Electric in 2022, operates through four core segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its product portfolio includes MRI and CT scanners, X-ray systems, ultrasound technologies, patient monitoring devices, and contrast media. The company also develops digital health solutions to enhance clinical decision-making and improve patient outcomes. With a strong presence in over 160 countries, GE HealthCare Technologies serves healthcare providers, radiologists, cardiologists, and researchers.

The Imaging segment offers a broad range of diagnostic equipment, including MRI systems, CT scanners, and womens health imaging solutions. AVS focuses on ultrasound technologies and interventional guidance systems used in cardiology, oncology, and womens health. PCS provides critical care devices such as patient monitors, anesthesia equipment, and maternal-infant care products. PDx specializes in diagnostic agents, including contrast media and radiopharmaceuticals, which are essential for enhancing the clarity of medical imaging procedures.

Based on the provided data, here is a 3-month forecast: - Price: The stock is currently trading at 60.48, below its 20-day SMA of 70.03. The 50-day SMA at 80.15 and 200-day SMA at 83.61 indicate a downtrend. Expect resistance near the 50-day SMA and support around the current price level. ATR of 3.15 suggests moderate volatility. - With a market cap of 28,555.67M and a P/E ratio of 14.37, the stock is fairly valued compared to its forward P/E of 13.26. A P/S ratio of 1.45 reflects moderate revenue scalability. The ROE of 23.60% highlights strong profitability. Expect earnings reports to drive short-term price movements. - Outlook: The stock may face resistance at 70-75 in the near term. Support is likely near 55-60. Earnings and revenue growth will be key drivers. The companys strong fundamentals and product portfolio position it for long-term growth, but short-term price action may remain choppy due to market conditions.